Asset Details
Do you wish to reserve the book?
Features of Atrial Fibrillation in Wild-Type Transthyretin Cardiac Amyloidosis: A Systematic Review and Clinical Experience
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Features of Atrial Fibrillation in Wild-Type Transthyretin Cardiac Amyloidosis: A Systematic Review and Clinical Experience
Do you wish to request the book?
Features of Atrial Fibrillation in Wild-Type Transthyretin Cardiac Amyloidosis: A Systematic Review and Clinical Experience
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Features of Atrial Fibrillation in Wild-Type Transthyretin Cardiac Amyloidosis: A Systematic Review and Clinical Experience
2018
Overview
Abstract
Aims
Wild-type transthyretin (ATTRwt) cardiac amyloidosis has emerged as an important cause of heart failure in the elderly. Atrial fibrillation (AF) commonly affects older adults with heart failure and is associated with reduced survival, but its role in ATTRwt is unclear. We sought to explore the clinical impact of AF in ATTRwt.
Methods and results
Patients with biopsy-proven ATTRwt cardiac amyloidosis (n = 146) were retrospectively identified, and clinical, echocardiographic, and biochemical data were collected. Patients were classified as AF or non-AF and followed for survival for a median of 41.4 ± 27.1 months. Means testing, univariable, and multivariable regression models were employed. A systematic review was performed. AF was observed in 70% (n = 102). Mean age was similar (AF, 75 ± 6 vs. non-AF, 74 ± 5 years, P = 0.22). Anticoagulant treatment of patients with AF was as follows: 78% warfarin, 17% novel anticoagulant, and 6% no anticoagulation. Amiodarone was prescribed to 24%. There were no differences in left ventricular ejection fraction (P = 0.09) or left atrial volume (P = 0.87); however, mean diastolic dysfunction grade was higher in AF (mean 2.7 ± 0.5 vs. 2.4 ± 0.5, P = 0.01). While creatinine (P = 0.52) and B-type natriuretic peptide (P = 0.48) were similar, patients with AF had lower serum transthyretin concentrations (221 ± 51 vs. 250 ± 52 μg/mL, P < 0.01). Survival between groups was similar (P = 0.46).
Conclusions
These data provide an evidence basis for clinical management and demonstrate that AF in ATTRwt does not negatively impact survival. Further analysis of the relationship between transthyretin concentration and AF development is warranted.
Publisher
Oxford University Press,John Wiley and Sons Inc
Subject
/ Amyloid Neuropathies, Familial - complications
/ Amyloid Neuropathies, Familial - diagnosis
/ Amyloid Neuropathies, Familial - epidemiology
/ Atrial Fibrillation - epidemiology
/ Atrial Fibrillation - etiology
/ Atrial Fibrillation - physiopathology
/ Biopsy
/ Dyspnea
/ Edema
/ Humans
/ Original
/ Patients
/ Proteins
